Joshua B. Davis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joshua B. Davis has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Antonia Faustina Chen
Department of Orthopaedics, University of Texas Southwestern, Dallas, Texas
1 shared publication - Bahar Entezari
Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
1 shared publication - Daniel C. Gabriel
From the Harvard Medical School, Boston, MA (Gabriel, Hines, and Prabhat); the Lenox Hill Hospital, New York, NY (Dr. Ang); and the Boston Children's Hospital, Department of Orthopedic Surgery, Boston, MA (Dr. Liu and Dr. Hogue)
1 shared publication - Jesse Isaac Wolfstadt
University of Toronto
1 shared publication - Johnathan Robert Lex
Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
1 shared publication - Margaret S. Juryn
Faculty of Medicine & Dentistry, University of Alberta; Granovsky Gluskin Division of Orthopaedics, Mount Sinai Hospital, Sinai Health
1 shared publication
Latest Publications
- 25 April 2025
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 107 (12) , 1324-1332
Successful Management of Periprosthetic Joint Infection Following Total Joint Arthroplasty, as Defined by the Patient
Background: The literature on the subjective experience of patients undergoing treatment for periprosthetic joint infection (PJI) following total joint arthroplasty (TJA) is scarce, and treatment success is defined without consideration of patient values. The primary objective of this study was to characterize the experience of patients undergoing PJI management. The secondary and tertiary aims were to identify factors that patients associate with successful treatment and to assess alignment with a 2019 outcome-reporting tool (ORT) by the Musculoskeletal Infection Society (MSIS). Methods: Patients treated for PJI at 2 international tertiary arthroplasty centers and for whom no less than 1 year and no more than 5 years had elapsed since their most recent revision surgery were included. From August 2023 to April 2024, patients participated in semistructured interviews with a phenomenological approach—an approach that aims to provide detailed examinations of personal lived experiences and to identify themes regarding how a particular phenomenon is experienced. Interview topics included experiences with primary TJA, PJI diagnosis and management, and patient perceptions of the success of their PJI management. Interviews were transcribed, and a thematic analysis was performed. The concordance between patient-defined and MSIS ORT-defined treatment success was calculated. Results: Of 27 total patients, 21 (78%) reported considerable mental health impacts during the period from PJI onset to treatment conclusion. In defining successful PJI management, patients consistently emphasized the importance of function, pain relief, mobility, and independence. Nine (33%) of the patients (p < 0.001) did not agree with their MSIS ORT classification of success versus failure. Conclusions: PJI is a devastating complication following TJA, and success as defined by patients does not align with success as defined by clinicians. As a result, there is insufficient support offered to patients throughout the PJI management process. Future avenues for research include the exploration of the feasibility and impact of implementing patient-centered care models that feature psychological support. Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
- 25 April 2025
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 107 (12) , 1324-1332
Successful Management of Periprosthetic Joint Infection Following Total Joint Arthroplasty, as Defined by the Patient
Background: The literature on the subjective experience of patients undergoing treatment for periprosthetic joint infection (PJI) following total joint arthroplasty (TJA) is scarce, and treatment success is defined without consideration of patient values. The primary objective of this study was to characterize the experience of patients undergoing PJI management. The secondary and tertiary aims were to identify factors that patients associate with successful treatment and to assess alignment with a 2019 outcome-reporting tool (ORT) by the Musculoskeletal Infection Society (MSIS). Methods: Patients treated for PJI at 2 international tertiary arthroplasty centers and for whom no less than 1 year and no more than 5 years had elapsed since their most recent revision surgery were included. From August 2023 to April 2024, patients participated in semistructured interviews with a phenomenological approach—an approach that aims to provide detailed examinations of personal lived experiences and to identify themes regarding how a particular phenomenon is experienced. Interview topics included experiences with primary TJA, PJI diagnosis and management, and patient perceptions of the success of their PJI management. Interviews were transcribed, and a thematic analysis was performed. The concordance between patient-defined and MSIS ORT-defined treatment success was calculated. Results: Of 27 total patients, 21 (78%) reported considerable mental health impacts during the period from PJI onset to treatment conclusion. In defining successful PJI management, patients consistently emphasized the importance of function, pain relief, mobility, and independence. Nine (33%) of the patients (p < 0.001) did not agree with their MSIS ORT classification of success versus failure. Conclusions: PJI is a devastating complication following TJA, and success as defined by patients does not align with success as defined by clinicians. As a result, there is insufficient support offered to patients throughout the PJI management process. Future avenues for research include the exploration of the feasibility and impact of implementing patient-centered care models that feature psychological support. Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.